Oblique Therapeutics Welcomes Dr. Jan Lundberg as a Scientific Advisor#Sweden#Gothenburg#Oblique_Therapeutics#Jan_Lundberg#Scientific_Advisor
Oblique Therapeutics Welcomes Dr. Jan Lundberg as a Scientific Advisor
Oblique Therapeutics has announced the appointment of Dr. Jan Lundberg as a Scientific Advisor, marking a major advancement in their innovative drug platform development.
third-news.com
May 8, 2026 at 9:14 AM
Oblique Therapeutics Welcomes Dr. Jan Lundberg as a Scientific Advisor#Sweden#Gothenburg#Oblique_Therapeutics#Jan_Lundberg#Scientific_Advisor
Oblique Therapeutics Welcomes Dr. Jan Lundberg as Scientific Advisor, Boosting Drug Development#Sweden#Gothenburg#Oblique_Therapeutics#Dr._Jan_Lundberg#TRPV1
Oblique Therapeutics Welcomes Dr. Jan Lundberg as Scientific Advisor, Boosting Drug Development
Oblique Therapeutics announces Dr. Jan Lundberg's appointment as Scientific Advisor, marking a critical step in their drug platform for pain management.
third-news.com
May 8, 2026 at 9:03 AM
Oblique Therapeutics Welcomes Dr. Jan Lundberg as Scientific Advisor, Boosting Drug Development#Sweden#Gothenburg#Oblique_Therapeutics#Dr._Jan_Lundberg#TRPV1
Oblique Therapeutics Secures SEK 14.1 Million in Fully Subscribed Rights Issue#Sweden#Gothenburg#Rights_Issue#Oblique_Therapeutics#SEK_14.1_Million
Oblique Therapeutics Secures SEK 14.1 Million in Fully Subscribed Rights Issue
Oblique Therapeutics AB successfully completed a fully subscribed rights issue, raising SEK 14.1 million to bolster its strategic initiatives and financial stability.
third-news.com
June 30, 2026 at 8:44 AM
Oblique Therapeutics Secures SEK 14.1 Million in Fully Subscribed Rights Issue#Sweden#Gothenburg#Rights_Issue#Oblique_Therapeutics#SEK_14.1_Million
Oblique Therapeutics Secures SEK 14.1 Million Through Successful Rights Issue#Sweden#Gothenburg#Oblique_Therapeutics#AbiProt#Christer_Nordstedt
Oblique Therapeutics Secures SEK 14.1 Million Through Successful Rights Issue
Oblique Therapeutics AB has successfully completed a rights issue, generating SEK 14.1 million. This funding is critical for advancing their projects and technology platform, AbiProt.
third-news.com
June 30, 2026 at 8:44 AM
Oblique Therapeutics Secures SEK 14.1 Million Through Successful Rights Issue#Sweden#Gothenburg#Oblique_Therapeutics#AbiProt#Christer_Nordstedt